Bio-Techne
Bio-Techne Receives IVDR Certification for Chronic Myeloid Leukemia Test
The qPCR-based test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with chronic myeloid leukemia to determine their response to treatment.
Bio-Techne Nabs CE Mark for HPV Head and Neck Cancer Test, Completes Namocell Acquisition
The RNAscope ISH Probe High Risk HPV test detects E6/E7 mRNA and is intended to help inform treatment selection in oropharyngeal squamous cell carcinoma patients.
Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says
Premium
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.